Serono Inc has launched Zorbtive (somatropin for injection) for the treatment of patients with short bowel syndrome, following US Food and Drug Administration approval at the end of last year (Marketletter December 8, 2003). Approval was granted on results from a pivotal clinical trial which demonstrated that a four-week regimen of the drug, administered together with a specialized diet, significantly reduced dependence on intravenous nutrition, as measured by total volume, total calories and infusion frequency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze